Gordon B Mills

This inventor holds 23 USPTO granted patents and 8 published patent applications, plus 1 CIPO patent and 1 EPO patent, primarily in Cancer Biomarkers. Top assignees: The University of Texas System, Millennium Pharmaceuticals Limited, Cytovia, Inc.. Active years: 1999-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Gordon B Mills. Retrieved from https://idiyas.com/inventor/gordon-b-mills

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 8)

% Patents Active = 56.5

CIPO Patents = 1

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 441(Granted Patents)

Company Filing History:

13 out of 5,640

The University of Texas System

patents

6 out of 855

Millennium Pharmaceuticals Limited

Nanostring Technologies, Inc.

patents

5. 2 out of 9

Bruker Spatial Biology, Inc.

patents

6. 2 out of 16,035

University of California

Mayo Foundation for Medical Education and Research

patents

9. 1 out of 1,075

The Cleveland Clinic Foundation

patents

10. 1 out of 1,993

University of South Florida

where one patent can have more than one assignee

Years Active: 1999-2026

Loading Chart...

Areas of Expertise:

Gene Expression

Cancer Therapy

Predictive Markers

Ovarian Cancer

Breast Cancer

Caspase Inhibitors

Protein Quantification

Genetic Alterations

Gynecological Carcinomas

Drug Response

Homologous Recombination

Therapeutic Kits

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12630869 - Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue (2026-05-19),

2. 12435361 - Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue (2025-10-07),

3. 11708602 - Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue (2023-07-25),

4. 11447830 - Gene signatures to predict drug response in cancer (2022-09-20),

5. 10640816 - Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue (2020-05-05),

6. 10533227 - Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer (2020-01-14),

7. 10501777 - Simultaneous quantification of a plurality of proteins in a user-defined region of a cross-sectioned tissue (2019-12-10),

8. 9850542 - Gene signature to predict homologous recombination (HR) deficient cancer (2017-12-26),

9. 9163091 - Compositions and methods for binding lysophosphatidic acid (2015-10-20),

10. 8404829 - Predictive and therapeutic markers in ovarian cancer (2013-03-26),

11. 8323906 - Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer (2012-12-04),

12. 8211646 - Methods of treating ovarian cancer by modulating SnoN (2012-07-03),

13. 8080368 - Compositions and methods for the identification, assessment, prevention and therapy of human cancers (2011-12-20),

14. 7871775 - Compositions and methods for the identification, assessment, prevention and therapy of human cancers (2011-01-18),

15. 7670767 - Genetic alterations associated with cancer (2010-03-02),

Title: **Gordon B Mills: A Visionary in Cancer Research and Therapeutics**

Introduction

Gordon B Mills is an esteemed inventor based in Houston, Texas, renowned for his significant contributions to the fields of molecular biology and cancer therapeutics. With an impressive portfolio of 21 patents, his work has potential applications in the diagnosis and treatment of various forms of cancer, pushing the boundaries of scientific research and innovation.

Latest Patents

Among his most recent inventions are two groundbreaking patents. The first, titled "Simultaneous quantification of gene expression in a user-defined region of a cross-sectioned tissue," provides methods, probes, and kits for the multiplexed detection and quantification of protein and/or nucleic acid expression. This invention allows for detailed analysis of specific regions in tissue samples, enhancing our understanding of cellular responses.

The second patent, "Gene signatures to predict drug response in cancer," focuses on identification and therapeutic methods for cancers with specific DNA repair deficiencies. This invention aims to improve treatments for cancers sensitive to PARP inhibitors or platinum-based therapies, highlighting the potential for personalized medicine in oncology.

Career Highlights

Gordon B Mills has had a remarkable career, particularly as a member of the University of Texas System, where his research has been pivotal in advancing cancer treatment methodologies. Additionally, he has made noteworthy contributions while working with Millennium Pharmaceuticals Limited, enhancing drug development and therapeutic strategies in cancer care.

Collaborations

Throughout his illustrious career, Mills has collaborated with prominent professionals in the field, including Robert C Bast and Eckard Weber. These partnerships have facilitated innovative research projects and fostered advancements that address critical issues in cancer treatment.

Conclusion

Gordon B Mills embodies the spirit of innovation in cancer research, with a focus on improving diagnosis and treatment options through his extensive patent portfolio. His contributions continue to have a profound impact on the scientific community and the effectiveness of cancer therapies, establishing him as a key figure in the ongoing fight against cancer.

Profile summary based on public USPTO records.